SEC Form 4	
------------	--

 \square

FORM	4
------	---

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Che	ck this box if no longer subject to
	tion 16. Form 4 or Form 5
obli	gations may continue. See
Inst	ruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	ROVAL
OMB Number:	3235-0287
Estimated average h	aurdon.

	0200	020.
Estimated average burde	en	
hours per response:		0.5

					01 3601		Investin		прану Аст	01 13	40						
1. Name and Address of Reporting Person [*] Arbuckle Stuart A					2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								eck all appli Directo Officer				uer vner specify
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 07/21/2015								below)		nmer	below) cial Offic	er
50 NORTHERN AVENUE (Street)					4. If Ame	endment, Date o	of Origin	al Filed	(Month/Da	ay/Yea	ar)	Line)		0	(Check Ap	
BOSTO	N M	Ā	02210									1	Form f	Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(S	tate)	(Zip)														
		Tal	ole I - Nor	n-Deriva	ative Se	curities Aco	quirec	, Dis	posed c	of, o	r Bene	eficiall	y Owned	l			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					ay/Year)	2A. Deemed 3. 4. Securities Acquired (A) Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) Disposed Of (D) (Instr. 3, 5)				Securitie Benefici Owned F	5. Amount of Securities Beneficially Owned Following Reported		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount		(A) or (D)	Price	Transact (Instr. 3	tion(s)			(1150. 4)
						urities Acqu s, warrants							Owned				
1. Title of 2. 3. Transaction 3A. Deemed 4.					ansaction	5. Number 6. Date Exercisable and 7. Title and Am					8. Price of			10. Ownership	11. Nature		

Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	(Month/Day/Year)	Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		Transaction of Code (Instr. Derivative		of Derivative Securities Acquired (A) or Disposed of (D) (Instr.		saction of e (Instr. Derivative Securities Acquired (A) or Disposed of (D) (Instr.		Expiration Date of S (Month/Day/Year) Und Deri		Expiration Date (Month/Day/Year)		of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares											
Stock Option	\$131.89	07/21/2015		А		34,000		(1)	07/20/2025	Common Stock	34,000	\$0.00	34,000	D		I						

Explanation of Responses:

1. The option vests in 16 quarterly installments from 07/21/2015.

Remarks:

Omar White, Attorney-In-Fact 07/23/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.